The FAM-GEM-1 study: Frequency and characteristics of familial melanoma in Spain.

Rodas, Iván Márquez; Martín-González, Manuel; Nagore, Eduardo; Fernández, Cristina Gómez; Izquierdo, Jose Antonio Avilés; Maldonado-Seral, Cayetana; Soriano, Virtudes; Majem, Margarita; Coloma, Virginia Palomar; Maseda, R.; Carnicero, Alfonso Martín; Puértolas, Teresa; Gijón, Elena Godoy; Cerezuela, Pablo; Olza, María Ochoa de; Balea, Begoña Campos; Ruíz, Elísabeth Pérez; Rivas, Ainara Soria; Gil-Arnaiz, Irene; Martín‐Algarra, Salvador

doi:10.1200/jco.2014.32.15_suppl.9039

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the great advantages of using DC vaccines for melanoma therapy is their safety and potent ability to combine with other immunotherapies as immunological check point inhibitors, either in patients or in experimental models (36)(37)(38)(39)(40).…”

Section: Trials With DC Vaccines For Melanomamentioning

confidence: 99%

Dendritic cell therapy in melanoma

et al. 2017

View full text Add to dashboard Cite

Dendritic cell (DC) vaccines are cancer vaccines used currently as melanoma therapies. They act as adjuvants initiating the immune responses, but not only as they can also have effector activities redirecting cytotoxic CD8 T cells against melanoma. Ex vivo preparation of monocyte derived DCs has been implemented to produce large numbers of DCs for clinical therapy, highlighting the necessity of activate DC s to produce Th1 cytokines, especially TNF-a and IL-12 with potent anti-tumour actions. Several clinical trials both in the European Union and USA are open currently using DC vaccines, alone or in combination with other immunotherapies. The type of antigen is also an active area of investigation involving tumour antigens and bacterial epitopes, both providing good responses. Bacterial epitopes presented the advantage versus tumour antigens that they can prepare the vaccination site as they induce innate and specific immune responses as they are potent recall antigens that expand cytotoxic responses.

show abstract

Section: Trials With DC Vaccines For Melanomamentioning

confidence: 99%

Dendritic cell therapy in melanoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…La piel clara, el número de nevus adquiridos y la presencia de nevus displásicos son los factores de riesgo constitucionales asociados 12 . Por otro lado, algunos estudios muestran que hasta un 11% de los pacientes afectados por melanoma en España tienen antecedentes familiares de melanoma [13][14][15] .…”

Section: Epidemiología Del Melanomaunclassified

Estudio de la mutación BRAFV600 en el melanoma cutáneo o primario y metastásico. Correlación con variables clínico-patológicas

Gijón¹

View full text Add to dashboard Cite

BRAFiInhibidor de BRAF BRAF M Mutación en el gen BRAF BRAF WT Ausencia de mutación en el gen BRAF o BRAF wild type BSGC Biopsia selectiva del ganglio centinela CDKN2A+ Inhibidor 2A de kinasa dependiente de ciclina CDK4 Kinasa dependiente de ciclina 4 CCD1 Ciclina D1 CEC Carcinoma epidermoide cutáneo CFC Cardio-facio-cutáneo c-Kit Receptor del factor de crecimiento de células madre c-Met Receptor tirosín-kinasa del hepatocyte growth factor (llamado también HGFR) CTLA-4 Cytotoxic T-lymphocyte-associated antigen 4 DTIC Dacarbacina EGFR Receptor del factor de crecimiento epidérmico EMA European Medicines Agency (Agencia Europea del Medicamento) ERK Extracellular-signal-regulated kinase FAS Antígeno de apoptosis 1 FasR Receptor Fas FDA Food and Drug Administration FLT-3 Fms-related tyrosine kinase-3 o fetal liver kinase (también llamado CD135)

show abstract

The FAM-GEM-1 study: Frequency and characteristics of familial melanoma in Spain.

Cited by 2 publications

References 0 publications

Dendritic cell therapy in melanoma

Dendritic cell therapy in melanoma

Estudio de la mutación BRAFV600 en el melanoma cutáneo o primario y metastásico. Correlación con variables clínico-patológicas

Contact Info

Product

Resources

About